Back to 2016 Annual Symposium ePosters
The Use of Aortic Unibody Endograft for Distal Aortic Stenosis and Aortoiliac Occlusive Disease
Arthelma C. Tyson, MD, Phyllis Suen, MD, Matthew D'Alessandro, DO, Kuldeep Singh, MD, Saqib Zia, MBBS, Jonathan A. Schor, MD, Jonathan S. Deitch, MD.
Staten Island University Hospital, Staten Island, NY, USA.
OBJECTIVES: Aortic unibody endografts may allow the use of endovascular techniques to treat distal aortic stenosis (DAS) and severe aortoiliac occlusive disease (AIOD). We reviewed our experience with the use of the Endologix AFX aortic endograft for patients with DAS and AIOD who were not candidates for traditional endovascular approaches.
METHODS: A prospective database was used to evaluate and track all patients who underwent endograft placement from the years 2010-2015. There were a total of 6 patients who had endograft placement for DAS or AIOD. Patient demographics, operative factors, complications, and resolution of symptoms were reviewed.
RESULTS: There were a total of 30 patients who had unibody aortoiliac endograft with the Endologix AFX endograft. Of those, 6 had the graft placed for DAS and/or AIOD. All had the indication of severe claudication. There were no patients with tissue loss or rest pain. Four patients had high-grade distal aortic stenosis with concomitant bilateral common iliac stenoses. One patient had left common iliac aretery stenosis and a small aortic aneurysm. Another had bilateral common iliac stenosis and bilateral distal common iliac artery aneurysms.
The mean patient age was 64 (51-71). The mean BMI was 31.2 (25-39.5). There were no cases of post-operative cardiovascular complications, return to OR, renal failure, wound infection, or reintubation. All 6 patients had resolution of symptoms following the procedure. The patients were followed by clinical exam and duplex ultrasound. The mean follow-up was 8 months (0.63-15.8 months). At last follow-up, all patients maintained patency of the endograft as confirmed by aortic duplex. In addition, all patients remained symptom-free.
CONCLUSIONS: Aortic endografting for the treatment of select patients with distal aortic stenosis and advanced aortoiliac occlusive disease utilizing the Endologix AFX system appears to be a safe treatment option. This may provide an endovascular option for patients who would otherwise have been treated with open surgery. Prospective studies are required to better evaluate long-term outcomes.
Back to 2016 Annual Symposium ePosters
|
